Vitiligo is a chronic autoimmune condition in which pigment-producing cells (melanocytes) are destroyed, resulting in irregular white patches on the skin. It affects approximately 1–2% of the global population, roughly 70 million people worldwide, and, while not medically dangerous in most cases, has profound psychological and social impact.
What Causes Vitiligo?
Vitiligo is an autoimmune disease. The immune system mistakenly identifies melanocytes as foreign and destroys them. Contributing factors include:
- Genetic predisposition, vitiligo runs in families
- Oxidative stress, melanocytes are particularly vulnerable to oxidative damage
- Other autoimmune conditions, vitiligo is more common in people with thyroid disease, type 1 diabetes, and alopecia areata
- Potential triggering events, sunburn, skin injury, and stress have been associated with onset or flaring
Types of Vitiligo
Nonsegmental vitiligo (the most common type), symmetrical patches appearing on both sides of the body, typically on the hands, face, and around body orifices. This type is progressive and autoimmune-driven.
Segmental vitiligo, patches confined to one segment of the body, unilateral. More stable; different immune mechanism.
The New Treatment Era
For most of vitiligo’s history, treatment options were limited, topical steroids, phototherapy, and calcineurin inhibitors, with modest outcomes.
In 2022, the FDA approved ruxolitinib cream (Opzelura), the first medication specifically indicated for repigmentation in nonsegmental vitiligo. As a topical JAK inhibitor, it blocks the inflammatory signaling that drives melanocyte destruction, producing genuine repigmentation, particularly on the face.
Ask about NuLine’s skin condition research to learn about clinical trial opportunities.